Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSF1 | Q00613 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | BCL6 | P41182 | 2/20 | 0.32 |
| ▸ | BCOR | Q6W2J9 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | VRK1 | Q99986 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766793 | 0.96 | HSF1 (0.43) | HSF1NTRK1BRD4DAOIGF1R | |
| SCHEMBL3766182 | 0.87 | IGF1R (0.45) | BRD4DAOIGF1RVRK1 | |
| SCHEMBL3763551 | 0.86 | APP (0.34) | DAOAPPVRK1 | |
| SCHEMBL13054545 | 0.85 | NTRK1 (0.55) | HSF1NTRK1BRD4IGF1R | |
| SCHEMBL13054561 | 0.83 | NTRK1 (0.53) | HSF1NTRK1BRD4IGF1R | |
| SCHEMBL6853854 | 0.80 | IGF1R (0.33) | NTRK1DAOIGF1R | |
| SCHEMBL6824078 | 0.80 | HSF1 (0.40) | HSF1NTRK1BRD4IGF1RABCG2 | |
| SCHEMBL3765122 | 0.79 | MKNK1 (0.35) | DAOAPPVRK1 | |
| SCHEMBL3768085 | 0.77 | MEN1 (0.34) | DAOAPPVRK1 | |
| SCHEMBL3768412 | 0.77 | HSF1 (0.46) | HSF1BRD4DAOABCG2VRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-20040167121-A1 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167121-A1 | Indazolinone compositions useful as kinase inhibitors | LCK, CDK2, CILK1 | HSF1 1539/4885NTRK1 1472/4885BRD4 757/4885 |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | HSF1 1593/4885NTRK1 1279/4885BRD4 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.